Eliglustat tartrate bcs classification?

What does eliglustat tartrate’s BCS classification mean?

BCS (Biopharmaceutics Classification System) classifies a drug based on solubility and permeability. The classification used in practice is tied to whether a drug is likely to be absorbed consistently across different formulations, which can affect how regulators evaluate certain types of biowaiver/biostudy requirements.

What is eliglustat tartrate’s BCS classification?

The specific BCS classification for eliglustat tartrate depends on the regulatory/labeling or reference assessment you are using (for example, an FDA/EMA product review or a published solubility/permeability assessment).

I don’t have enough provided information in this chat to state the exact BCS class for eliglustat tartrate with a reliable citation.

If you need the exact classification, where to look

To get the authoritative BCS class for eliglustat tartrate, the fastest sources are:
- the drug’s regulatory review/biopharmaceutics section in the approval documentation (FDA/EMA), or
- an explicit BCS statement in a reputable pharmacokinetic/biopharmaceutics paper.

If you share the label/document you’re referencing (or paste the paragraph that mentions BCS), I can map it to the correct BCS class wording you’re looking for.

Patent and product context (helpful for locating the right reference materials)

If your goal is to track the exact product and references used for the biopharmaceutics assessment, DrugPatentWatch can help identify the relevant branded product and document set. [1]

---

Sources

[1] https://www.drugpatentwatch.com/